Selskabsmeddelelse

Annexin engages Pareto Securities as liquidity provider

Annexin Pharmaceuticals AB (publ) today announces that the company has entered into an agreement with Pareto Securities AB to act as liquidity provider for Annexin's shares, listed on Nasdaq First North Growth Market. The assignment will start to run from January 30, 2026.

The purpose of the liquidity guarantee is to promote good liquidity in the share and to reduce the spread between bid and ask prices during ongoing trading. This means that Pareto Securities undertakes to continuously place trading entries on each buy and sell side of the order book. The undertaking is made in accordance with Nasdaq First North Growth Market's rules for liquidity providers.

The assignment will start to run from January 30, 2026.

About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals is a clinical stage biotechnology company active in the therapeutic areas ophthalmology and oncology. The company develops ANXV, a recombinant human Annexin A5 protein, as a first-in-class biologic with potentially disease-modifying mechanisms of action. The ANXV program is currently in Phase 2 in ophthalmology for retinal vein occlusion (RVO) and diabetic retinopathy (DR) and in pre-clinical stage in oncology.
The company is based in Stockholm and listed on Nasdaq First North Growth Market Sweden under the ticker ANNX. Redeye is the company's Certified Adviser.